Category: Research Guides

  • How to Reconstitute a Research Peptide: The Math, Step by Step

    A lyophilized peptide arrives as a small white cake or a film at the bottom of a sealed vial. Reconstitution is the step where that solid is dissolved into a liquid of a known concentration so it can be measured, aliquoted, and used in whatever assay or model the work calls for. Nothing about the peptide changes chemically when you do this correctly — you are not activating it or mixing it. You are only choosing a number: how many milligrams sit in each milliliter of the resulting solution.

    That number is where most avoidable errors happen. The arithmetic is simple, but the assumptions buried underneath it — what the label actually promises, how much peptide never makes it out of the vial, how the solution behaves over the following weeks — are where measured results drift away from intended ones.

    This guide covers how to reconstitute peptides for laboratory work: the math first, then the parts of the process that the published formulation literature says actually move the number.

    The Only Equation You Need

    Concentration equals mass divided by volume:

    C = m ÷ V

    Where m is the mass of peptide in the vial (in mg), V is the volume of diluent added (in mL), and C is the resulting concentration (in mg/mL).

    Everything else is rearrangement.

    Example 1: You have a vial and a volume

    A 10 mg vial reconstituted with 2 mL of diluent:

    C = 10 mg ÷ 2 mL = 5 mg/mL

    Example 2: You have a target concentration

    You have a 5 mg vial and you want a 2 mg/mL stock. Rearranged, V = m ÷ C:

    V = 5 mg ÷ 2 mg/mL = 2.5 mL

    Example 3: Working in micrograms

    Vials in the 2–5 mg range are often more convenient to express in µg/mL. A 5 mg vial in 5 mL of diluent is 1 mg/mL, which is 1,000 µg/mL, which is 1,000 µg per 1.00 mL — or 10 µg per 0.01 mL.

    Reading small volumes off a graduated 1 mL syringe

    A 1 mL syringe marked in 100 graduations puts one graduation at 0.01 mL. That is a fact about the barrel, not about the peptide, and it is the most common source of a factor-of-ten error in a lab notebook.

    To convert: mass per graduation = concentration (mg/mL) × 0.01

    At 5 mg/mL, one graduation (0.01 mL) holds 0.05 mg, or 50 µg. At 2 mg/mL, the same graduation holds 20 µg. The graduations do not change when the concentration does — only the mass they carry.

    A useful habit is to pick your diluent volume so the arithmetic lands on round numbers. Reconstituting a 10 mg vial to exactly 1 mg/mL means every 0.1 mL is 100 µg, and the conversion stops being a place where mistakes live.

    The Label Mass Is Not Always the Peptide Mass

    Here is the assumption the equation quietly makes: that a vial labeled 10 mg contains 10 mg of peptide. Often it does not, for three reasons that have nothing to do with anyone cutting corners.

    Counterion salt. Synthetic peptides are typically purified by reversed-phase HPLC using trifluoroacetic acid, and they come off that process as a salt. The basic residues in the sequence carry counterions that add mass. A vial weighed out as 10 mg of powder can contain meaningfully less than 10 mg of peptide.

    Residual moisture. Lyophilized material retains water, and the amount depends on the drying cycle.

    Fill tolerance. Filling equipment has a tolerance, and vials are commonly overfilled slightly to guarantee the labeled minimum.

    The consensus recommendations published in Clinical Chemistry for peptides used in quantitative mass-spectrometry assays are direct about this: gravimetric weight is not a reliable measure of peptide content, and amino acid analysis is the reference method when the actual quantity matters (Hoofnagle et al., Clin Chem 2016;62(1):48–69). That paper is written for assay developers, but the underlying problem is identical for anyone dissolving a vial and writing a concentration on the side of it.

    The practical version: a documented net peptide content figure belongs on the certificate of analysis alongside purity. If you are not sure what to look for, our walkthrough on how to read a certificate of analysis covers which sections carry that information and which do not.

    Choosing a Diluent

    Diluent choice is a solubility and stability question, not a preference.

    Sterile Water for Injection contains nothing but water. It has no antimicrobial component, which is why it is specified for single-entry use.

    Bacteriostatic Water for Injection is water with benzyl alcohol added as a preservative. Per the FDA-approved labeling, the concentration is 0.9% (9 mg/mL) in 30 mL plastic multiple-dose vials and 1.1% (11 mg/mL) in 20 mL glass vials, with a pH of 5.7 (range 4.5–7.0). The label carries a prominent warning against use in neonates, notes that the solution is not isotonic on its own, and specifies aseptic technique for every entry (DailyMed, Bacteriostatic Water for Injection, USP).

    Benzyl alcohol is not inert toward every polypeptide. It has been studied specifically as a destabilizing cosolute in protein formulations: hydrogen–deuterium exchange work showed benzyl alcohol loosening the structure of interferon-gamma (Tobler et al., J Pharm Sci 2004;93(6):1605–17), a later study characterized its role in the unfolding and aggregation of interferon α-2a (Bis et al., J Pharm Sci 2015;104(2):407–15), and aggregation of recombinant human IL-1 receptor antagonist increased in reconstituted lyophilized formulations containing it (Roy et al., J Pharm Sci 2005;94(2):382–96). Those studies used folded proteins, which have more structure to lose than a short linear peptide does — the finding does not transfer automatically. It does mean the diluent is a variable worth recording rather than an afterthought.

    Poorly soluble sequences. Solubility tracks with charge. Peptides rich in basic residues generally dissolve in dilute acid; acidic sequences in dilute base; strongly hydrophobic sequences may need an organic cosolvent such as DMSO or acetonitrile before dilution into aqueous buffer. Supplier technical notes — Bachem’s handling and storage guidelines are a good reference set — give sequence-based starting points. In vitro work is where organic cosolvents are relevant; the cosolvent then becomes part of the experimental condition and needs a vehicle control.

    Technique That Changes the Number

    Three habits show up consistently in peptide and protein formulation guidance.

    Add the diluent slowly, down the side wall. Directing a stream straight onto a lyophilized cake drives foaming, and the air–liquid interface is a known site of aggregation and denaturation in peptide and protein formulations (Manning et al., Pharm Res 2010;27(4):544–75).

    Swirl, do not shake. Let the vial stand and dissolve. Vigorous agitation and vortexing generate the same interfacial stress.

    Do not force a cloudy solution. A clear solution is the expected endpoint. Persistent haze, visible particulates, or a cake that will not dissolve is information about solubility or material quality, not something to be resolved with more shaking.

    The Loss You Cannot See

    Peptides adsorb to container surfaces, and at low concentration the effect is not small. In a controlled study of three cationic peptides, recovery from standard borosilicate glass vials and standard polypropylene tubes was as low as 10–20% after one hour — meaning 80–90% of the peptide was on the walls rather than in solution. Low-binding polypropylene tubes reduced the loss substantially, and recovery improved at higher peptide concentrations and at larger volume-to-surface-area ratios (Kristensen et al., PLoS One 2015;10(5):e0122419).

    That result is specific to cationic peptides at dilute concentrations, and it does not mean every vial loses most of its contents. It does mean that the concentration you calculated is an upper bound, that dilute working solutions are where the discrepancy is largest, and that low-binding labware and minimizing the number of transfer steps are cheap corrections. The Clinical Chemistry recommendations cited above make the same point for stock and working solutions.

    After Reconstitution: Storage and Aliquoting

    Once in solution, a peptide is exposed to hydrolysis, oxidation, and deamidation pathways that are effectively frozen in the dry state. Manning and colleagues catalog those routes in detail for peptide and protein pharmaceuticals.

    Repeated freeze–thaw cycling is a separate mechanical stress. Work on protein therapeutics has shown that freeze–thaw damage is driven by identifiable, controllable conditions — freezing rate, container, excipients — rather than being an unavoidable cost of cold storage (Jain et al., Sci Rep 2021;11:11332). The operational conclusion is the same one every peptide supplier gives: aliquot once into single-use portions rather than thawing and refreezing a single stock.

    Practical defaults, none of which are a substitute for stability data on your specific sequence: keep lyophilized material cold and dry until the moment it is used; keep reconstituted solution refrigerated and protected from light; aliquot for frozen storage; and treat any solution whose appearance has changed as compromised.

    Keep the Record

    Reconstitution is the point where a documented vial becomes an undocumented solution unless you write it down. A minimal entry: compound, supplier, lot number, labeled mass, net peptide content if reported, diluent and its lot, volume added, calculated concentration, date and time, storage location.

    Six weeks later, the difference between a usable stock and an unknown liquid is entirely that note.

    What the Math Does Not Tell You

    Concentration is an input to an experiment, not a conclusion about one. Calculating a stock correctly says nothing about whether a compound has been characterized in a given model, what has been observed in vitro versus in rodents versus in controlled human trials, or what any of it means. Those are separate questions, and the compound-by-compound summaries in our research peptides reference and the broader peptide education library are where the published record for individual sequences is laid out. For a worked example of how thin the evidence base can be even for a widely discussed compound, the BPC-157 research guide is a useful reality check.

    Get the arithmetic right, record the assumptions, and the number on the vial means something. That is the entire job.


    For laboratory and research use only. Not for human or animal consumption.

  • Ipamorelin vs CJC-1295: Growth-Hormone Secretagogues Compared

    Ipamorelin and CJC-1295 are two of the most-studied compounds in growth-hormone-axis research, and they’re often mentioned together. That pairing isn’t an accident: they act on different parts of the same system, which is exactly why researchers compare them. Here’s how they differ and why they’re frequently studied side by side.

    Everything below is for a research-use-only (RUO) context. These compounds are studied in cell and animal models; nothing here is guidance for human or veterinary use.

    The short answer

    Ipamorelin is a growth-hormone secretagogue — it acts on the ghrelin/GHS receptor to prompt a clean, pulse-like release of growth hormone. CJC-1295 is a GHRH analog — it mimics growth-hormone-releasing hormone and acts on the GHRH receptor to sustain GH-releasing activity. Two different receptors, two different levers on the same axis.

    What each one is

    Ipamorelin

    Ipamorelin is a selective growth-hormone secretagogue. Its defining trait in the research literature is selectivity: it stimulates GH release through the GHS/ghrelin receptor without strongly affecting other hormones like cortisol or prolactin, which makes it a comparatively “clean” tool for isolating GH-release effects. See our Ipamorelin research guide for more.

    CJC-1295

    CJC-1295 is an analog of growth-hormone-releasing hormone (GHRH). Rather than mimicking ghrelin, it engages the GHRH receptor to extend the signal that tells the body to release growth hormone. That sustained-release angle is why it’s studied as a longer-acting GHRH tool. Our CJC-1295 research guide covers the background.

    Side by side

    Ipamorelin CJC-1295
    Class GH secretagogue (ghrelin/GHS receptor) GHRH analog (GHRH receptor)
    Lever on the axis Mimics ghrelin Mimics GHRH
    Noted for Selective, pulse-like GH release Sustained GH-releasing activity
    Research focus Clean GH-release signaling Prolonged GHRH signaling
    Form Lyophilized powder Lyophilized powder

    Why they’re studied together

    The growth-hormone axis has more than one control point. GHRH (which CJC-1295 imitates) and ghrelin (which Ipamorelin imitates) push GH release through separate receptors. Because they act on different levers, study designs sometimes examine them in parallel to understand how the two signals behave — independently and in combination. The comparison isn’t about which is stronger; it’s about which control point a given research question is probing.

    Handling and quality

    Both are supplied lyophilized and follow standard peptide storage practice once reconstituted for research. And as always, the value of any GH-axis study depends on knowing exactly what’s in the vial — research-grade material should arrive with a current third-party Certificate of Analysis confirming identity and 99%+ purity.

    Bottom line

    Ipamorelin works the ghrelin/GHS lever for selective, pulse-like GH release; CJC-1295 works the GHRH lever for sustained signaling. They’re complementary tools on the same axis — match the one you use to the receptor your research question targets, and verify purity first.

    For laboratory and research use only (RUO). Not for human or veterinary use, consumption, or therapeutic application. No claims are made to diagnose, treat, cure, or prevent any condition.

  • Semaglutide vs Tirzepatide: GLP-1 Research Compared

    Semaglutide and Tirzepatide are the two names that dominate modern incretin research, and they’re often compared directly. Both are studied for their effects on the incretin system — the hormonal signaling that helps regulate glucose and metabolism — but they are built differently and act on a different number of targets. Here’s what actually separates them.

    Everything below is for a research-use-only (RUO) context. These compounds are studied in cell and animal models; nothing here is guidance for human or veterinary use.

    The short answer

    Semaglutide is a single-target compound: a GLP-1 receptor agonist. Tirzepatide is a dual-target compound: it acts on both the GIP receptor and the GLP-1 receptor. That difference — one incretin pathway versus two — is the core of every comparison between them, and it’s why Tirzepatide is often described as the “dual agonist” benchmark in metabolic research.

    What each one is

    Semaglutide

    Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 is one of the body’s incretin hormones, and research around Semaglutide focuses on how sustained GLP-1 receptor activation influences glucose regulation, insulin signaling, and appetite pathways in metabolic models. It’s frequently used as the reference point for GLP-1 research. See our Semaglutide research guide for more.

    Tirzepatide

    Tirzepatide is a dual agonist — it activates both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 receptor. GIP is a second incretin hormone, and the theory behind hitting both is that the two pathways may complement each other in metabolic signaling. That’s why Tirzepatide research is often framed around comparing single- versus dual-incretin activation. Our Tirzepatide research guide covers the details.

    Side by side

    Semaglutide Tirzepatide
    Class GLP-1 receptor agonist Dual GIP / GLP-1 receptor agonist
    Targets One (GLP-1) Two (GIP + GLP-1)
    Research focus Glucose regulation, appetite pathways Dual-incretin metabolic signaling
    Role in the literature GLP-1 reference compound Dual-agonist benchmark
    Form Lyophilized powder Lyophilized powder

    Why the target count matters

    The incretin system doesn’t rely on a single hormone. By adding GIP-receptor activity to GLP-1 activity, Tirzepatide gives researchers a way to study whether engaging two incretin pathways at once produces effects that differ from engaging one. Semaglutide, by staying GLP-1-only, is the cleaner tool for isolating what the GLP-1 pathway does on its own. Neither is “more advanced” in the abstract — they answer different questions.

    Handling and quality

    Both arrive lyophilized and follow standard peptide storage practice once reconstituted for research. As with any incretin compound, the result of a study is only as trustworthy as the material behind it — which is why research-grade Semaglutide and Tirzepatide should come with a current third-party Certificate of Analysis confirming identity and 99%+ purity.

    Bottom line

    Semaglutide is the single-pathway GLP-1 reference; Tirzepatide is the dual-pathway GIP/GLP-1 benchmark. Choose based on whether the research question is about one incretin pathway or the interaction of two — and verify purity either way.

    For laboratory and research use only (RUO). Not for human or veterinary use, consumption, or therapeutic application. No claims are made to diagnose, treat, cure, or prevent any condition.

  • BPC-157 vs TB-500: Which Peptide for Tissue-Repair Research?

    BPC-157 and TB-500 are the two peptides that come up most often in tissue-repair research, and they’re frequently mentioned in the same breath. They are not, however, the same kind of molecule, and they’re studied for different reasons. This guide breaks down what actually separates them — origin, structure, the mechanisms researchers focus on, and how they’re handled in the lab — so you can tell which one fits a given research question.

    Everything below is written for a research-use-only (RUO) context. These compounds are studied in cell and animal models; nothing here is guidance for human or veterinary use.

    The short answer

    BPC-157 is a stable, 15-amino-acid peptide derived from a protein found in gastric juice, and most of the research around it looks at angiogenesis (new blood-vessel formation) and growth-factor signaling in tendon, ligament, and gut-tissue models. TB-500 is a synthetic version of the active region of Thymosin Beta-4, a protein central to actin regulation, and its research centers on cell migration and wound healing. In short, they approach the repair process from two different angles: vascular and growth-factor signaling on one side, cytoskeletal and cell-movement signaling on the other.

    What each one is

    BPC-157

    BPC-157 (short for “Body Protection Compound-157”) is a synthetic pentadecapeptide — a chain of 15 amino acids — based on a sequence identified in human gastric juice. Its defining practical trait is stability: it stays intact under conditions that would degrade many peptides. In the literature it appears largely in animal and in-vitro models of tendon, ligament, muscle, and gastrointestinal repair. Our BPC-157 research guide covers its background in more depth.

    TB-500

    TB-500 is a synthetic peptide corresponding to the biologically active region of Thymosin Beta-4 (often written Tβ4), a 43-amino-acid protein found in nearly every cell type. Thymosin Beta-4’s best-characterized job is binding and regulating actin, one of the core building blocks of the cell’s internal scaffolding. Because cell migration depends on actin remodeling, TB-500 research tends to focus on movement and wound-closure models. See our TB-500 research guide for the full picture.

    Side by side

    BPC-157 TB-500
    Origin Sequence found in gastric juice Active region of Thymosin Beta-4
    Size 15 amino acids ~17-amino-acid active fragment
    Research focus Tendon, ligament, gut, muscle Wound healing, cell migration, cardiac & corneal
    Mechanism emphasis Angiogenesis, growth-factor signaling Actin regulation, cell migration
    Form Lyophilized powder Lyophilized powder
    Notable trait Unusually stable Standard peptide handling

    The mechanisms researchers focus on

    BPC-157 is most often discussed in relation to angiogenesis and growth-factor pathways. Studies frequently examine its relationship to VEGFR2 signaling and nitric-oxide pathways, both of which are tied to blood-vessel formation and the delivery of resources a tissue needs to rebuild. That vascular angle is a big part of why it shows up in tendon and ligament models, where blood supply is a known limiting factor.

    TB-500 / Thymosin Beta-4 works further “upstream” in the cell. By sequestering actin monomers, Thymosin Beta-4 influences how quickly cells can reorganize their scaffolding — and therefore how readily they migrate into an area that needs repair. Research models built around endothelial cells, keratinocytes, and wound closure lean on exactly this property.

    Why they’re often studied together

    Because the two peptides act on different parts of the repair cascade — one leaning vascular and growth-factor, the other leaning cytoskeletal and migratory — some study designs examine them in parallel rather than treating them as interchangeable. The comparison isn’t “which is better,” it’s “which mechanism does the research question actually target.” A model probing new blood-vessel formation and a model probing cell migration are asking different things.

    Handling in the lab

    Both arrive as a lyophilized (freeze-dried) powder and are reconstituted before use in research. BPC-157’s stability gives it a bit more tolerance for handling, while TB-500 follows standard peptide storage practice — kept cold, protected from repeated freeze-thaw cycles, and used within a reasonable window once in solution. In either case, the number that matters most before any of this is purity.

    Quality matters more than which one you pick

    Whichever compound a study uses, an impure or mislabeled peptide undermines the result before the work even begins. That’s why research-grade material should arrive with a current, third-party Certificate of Analysis (COA) confirming identity and 99%+ purity. If you can’t verify what’s in the vial, you can’t stand behind what comes out of the experiment. Purity is the baseline, not the upgrade.

    Bottom line

    BPC-157 and TB-500 are not rivals so much as two different tools. If a research question centers on angiogenesis, growth-factor signaling, or connective-tissue models, BPC-157 is the more studied fit. If it centers on cell migration and wound closure, TB-500’s link to actin regulation is the reason it’s chosen. Match the peptide to the mechanism — and make sure whatever you use is COA-verified.

    For laboratory and research use only (RUO). Not for human or veterinary use, consumption, or therapeutic application. No claims are made to diagnose, treat, cure, or prevent any condition.

  • Melanotan II

    Research Guide · Laboratory Use Only

    Melanocortin agonist

    Melanotan II is a synthetic analog of α-MSH and a broad melanocortin-receptor agonist, studied mainly for pigmentation biology.

    What it is

    Melanotan II activates several melanocortin receptors, including MC1R (linked to melanin synthesis) and MC4R. Its research profile spans pigmentation pathways and, through MC4R, appetite and behavioral signaling.

    How it’s studied

    Research focuses on melanocortin-receptor biology and melanin-synthesis pathways.

    Research focus areas

    • MC1R signaling and melanin synthesis
    • Broad melanocortin-receptor activation
    • Pigmentation-pathway research
    • MC4R-linked appetite signaling

    Handling & documentation

    In the laboratory this material is typically supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic or sterile water for in-vitro work. As with any research compound, the quality signal that matters most is a lot-specific Certificate of Analysis (COA) from an independent lab, confirming identity by mass spectrometry and purity by HPLC. Store per the supplier’s guidance and verify the COA before use.

    Browse the COA-verified research catalog →

    For laboratory research use only. This content is educational and written for a research context. The compound is a research-use-only (RUO) material — not a drug, supplement, food, or cosmetic, not for human or veterinary use, and no claims are made to diagnose, treat, cure, or prevent any condition. No dosing or protocols are provided.
  • Kisspeptin-10

    Research Guide · Laboratory Use Only

    Reproductive neuropeptide

    Kisspeptin-10 is a fragment of kisspeptin, a neuropeptide that sits at the top of the reproductive hormone cascade.

    What it is

    Kisspeptin-10 is studied for stimulating GnRH release from the hypothalamus, which in turn drives LH and FSH signaling. This makes it a key research tool for probing the upstream control of the reproductive (HPG) axis.

    How it’s studied

    Research interest centers on GnRH regulation and the hypothalamic-pituitary-gonadal axis.

    Research focus areas

    • GnRH-release signaling
    • Hypothalamic-pituitary-gonadal (HPG) axis research
    • LH and FSH downstream regulation
    • Reproductive-neuroendocrinology models

    Handling & documentation

    In the laboratory this material is typically supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic or sterile water for in-vitro work. As with any research compound, the quality signal that matters most is a lot-specific Certificate of Analysis (COA) from an independent lab, confirming identity by mass spectrometry and purity by HPLC. Store per the supplier’s guidance and verify the COA before use.

    Browse the COA-verified research catalog →

    For laboratory research use only. This content is educational and written for a research context. The compound is a research-use-only (RUO) material — not a drug, supplement, food, or cosmetic, not for human or veterinary use, and no claims are made to diagnose, treat, cure, or prevent any condition. No dosing or protocols are provided.
  • NAD+

    Research Guide · Laboratory Use Only

    Coenzyme

    NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell and central to energy metabolism and cellular repair signaling.

    What it is

    NAD+ is studied as a substrate for sirtuins and PARP enzymes and as a carrier in cellular energy (redox) reactions. Because NAD+ levels are studied in the context of aging, it is a major reference molecule in longevity and mitochondrial research.

    How it’s studied

    Research spans cellular energy metabolism, DNA-repair signaling, sirtuin biology, and aging models.

    Research focus areas

    • Cellular energy (redox) metabolism
    • Sirtuin and PARP enzyme substrate biology
    • DNA-repair signaling
    • Longevity and mitochondrial research

    Handling & documentation

    NAD+ is a coenzyme typically supplied as a powder for in-vitro laboratory research. Confirm identity and purity against a lot-specific Certificate of Analysis (COA) from an independent lab, and store per the supplier’s guidance.

    Browse the COA-verified research catalog →

    For laboratory research use only. This content is educational and written for a research context. The compound is a research-use-only (RUO) material — not a drug, supplement, food, or cosmetic, not for human or veterinary use, and no claims are made to diagnose, treat, cure, or prevent any condition. No dosing or protocols are provided.
  • PT-141 (Bremelanotide)

    Research Guide · Laboratory Use Only

    Melanocortin agonist

    PT-141 (bremelanotide) is a melanocortin-receptor agonist derived from Melanotan II, studied primarily in the context of sexual-function research.

    What it is

    Unlike vascular-acting compounds, PT-141 is studied for acting through central melanocortin receptors (notably MC4R) in the nervous system rather than directly on blood vessels.

    How it’s studied

    Research focuses on melanocortin signaling and central pathways related to sexual response.

    Research focus areas

    • MC4R and central melanocortin signaling
    • Sexual-function research models
    • Nervous-system versus vascular mechanisms
    • Melanocortin-receptor pharmacology

    Handling & documentation

    In the laboratory this material is typically supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic or sterile water for in-vitro work. As with any research compound, the quality signal that matters most is a lot-specific Certificate of Analysis (COA) from an independent lab, confirming identity by mass spectrometry and purity by HPLC. Store per the supplier’s guidance and verify the COA before use.

    Browse the COA-verified research catalog →

    For laboratory research use only. This content is educational and written for a research context. The compound is a research-use-only (RUO) material — not a drug, supplement, food, or cosmetic, not for human or veterinary use, and no claims are made to diagnose, treat, cure, or prevent any condition. No dosing or protocols are provided.
  • DSIP

    Research Guide · Laboratory Use Only

    Neuropeptide

    DSIP (delta sleep-inducing peptide) is a naturally occurring neuropeptide first identified for its association with delta-wave sleep.

    What it is

    DSIP is studied for influencing sleep architecture and for interactions with stress-hormone and neuroendocrine systems. Its precise receptor targets remain an active research question, which is itself part of the interest.

    How it’s studied

    Research interest centers on sleep regulation, stress response, and neuroendocrine signaling.

    Research focus areas

    • Delta-wave sleep and sleep-architecture models
    • Stress-hormone and neuroendocrine interactions
    • Circadian and neuromodulatory research
    • Endogenous neuropeptide biology

    Handling & documentation

    In the laboratory this material is typically supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic or sterile water for in-vitro work. As with any research compound, the quality signal that matters most is a lot-specific Certificate of Analysis (COA) from an independent lab, confirming identity by mass spectrometry and purity by HPLC. Store per the supplier’s guidance and verify the COA before use.

    Browse the COA-verified research catalog →

    For laboratory research use only. This content is educational and written for a research context. The compound is a research-use-only (RUO) material — not a drug, supplement, food, or cosmetic, not for human or veterinary use, and no claims are made to diagnose, treat, cure, or prevent any condition. No dosing or protocols are provided.
  • Epithalon

    Research Guide · Laboratory Use Only

    Longevity-research peptide

    Epithalon (epitalon) is a synthetic tetrapeptide based on a fragment of the pineal peptide epithalamin, studied in longevity and cellular-aging research.

    What it is

    Epithalon is studied for its reported ability to activate telomerase and influence telomere maintenance in cell models, along with effects on melatonin and circadian signaling via the pineal axis.

    How it’s studied

    Research focuses on telomere biology, cellular aging, and pineal/circadian regulation.

    Research focus areas

    • Telomerase activity and telomere maintenance
    • Cellular-aging research models
    • Pineal-axis and melatonin signaling
    • Circadian-regulation studies

    Handling & documentation

    In the laboratory this material is typically supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic or sterile water for in-vitro work. As with any research compound, the quality signal that matters most is a lot-specific Certificate of Analysis (COA) from an independent lab, confirming identity by mass spectrometry and purity by HPLC. Store per the supplier’s guidance and verify the COA before use.

    Browse the COA-verified research catalog →

    For laboratory research use only. This content is educational and written for a research context. The compound is a research-use-only (RUO) material — not a drug, supplement, food, or cosmetic, not for human or veterinary use, and no claims are made to diagnose, treat, cure, or prevent any condition. No dosing or protocols are provided.